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Abstract 
Current therapies have nominal effect on the most intrusive-type of breast cancers (triple-
negative) that have a higher tendency to metastasize or recur. Recent studies reveal an enzyme, 
telomerase, as key for unlimited cell growth (immortality) and replication. Therefore, our 
objectives were to assess (i) short- and (ii) long-term effects of a novel anti-telomerase agent 
(GV6) developed at our institute and compare it to a known analogue, BIBR1532 on MDA-MB 
231 breast cancer cells. Cell viability was measured on days 5, 9, 14, 18 and 27 after treatment 
with GV6 (n=4), BIBR1532 (n=4) or Solvent alone (Control, n=3). The number of viable cells in 
GV6 and BIBR1532 treated flasks (T75) were about 40% (p<.05) of Control by day 14. It further 
dropped to 30% (p<.05) of Control by day 27 for both, GV6 and BIBR1532. Our results indicate 
the anti-proliferative effect of GV6 parallels that of BIBR1532 and should be investigated 
further. 
 
Introduction 
During 2013 alone, we estimate about 1,700,000 new cases of cancer to be diagnosed in 
the United States, leading to almost 1,600 deaths per day. Of the new cases, about 240,000 will 
be attributed to breast cancers diagnosed among women bringing with it a fatality rate of 
approximately 40,000 from this disease (1), making it one of the most deadly cancers. There are 
three key receptors that are commonly known to be triggers for breast cancer: the estrogen 
receptor, the progesterone receptor, and the human epidermal growth factor receptor. When a 
type of cancer has one or more of these receptors, it is considered to be “positive” for that 
specific receptor; while on the other hand, if the cancer does not have that receptor then it is 
considered to be “negative.” About 10-20% of all breast cancers diagnosed are a form of triple 
negative breast cancer (TNBC) because they lack these three pivotal hormone receptors, making 
TNBC the most aggressive type due to the high mortality rate. TNBCs exhibit a greater 
resistance towards the standard therapeutic procedures, requiring a more intrusive form of radio-
/chemo-therapies and even multiple surgeries to combat the higher metastatic and reoccurrence 
rates, confining the patient to a prolonged time for convalescence. Unfortunately the previously 
mentioned therapies are not capable of selectively targeting cancer cells specifically and 
decimate both cancerous and healthy cells. The insurmountable side effects (hair loss, organ 
damage, possible metastasis, secondary cancers etc.) of the current treatments have lead to an 
increase in the collaborative efforts towards finding a new therapy to combat the disease through 
the use of more precise agents.  
Recent studies regard the over-expression of a particular reverse transcription (RT) 
enzyme, Telomerase, as a pivotal indicator of the immortalization in 80%-90% of cancers (2). 
Reverse transcriptase enzymes gain most of their notoriety for their crucial role in the 
propagation of the HIV epidemic. Although these enzymes are similar and have the same 
function, these RT enzymes are not the same. This dual part RT enzyme has a RNA template that 
allows it to work in tandem with the catalytic part of the enzyme specific for humans, human 
telomerase reverse transcriptase (hTERT), to elongate the protective end-caps (telomeres) of the 
chromosomes through the addition of many repeats of the same base pair series TTAGGG. 
Telomeres will naturally reduce by approximately 30-120 base pairs with subsequent cycles of 
cellular replication with no means of elongation in normal somatic cells. Healthy cells without an 
active telomerase expect a set number of population doublings, known as the Hayflick limit, 
before entering a state of replicative inactivity known as cellular senescence (3). Without this 
growth arrest, a cell would perpetually divide and eventually damage genetic code crucial to the 
survival of the cell, thus activating a DNA damage response apoptotic pathway. Therefore, 
extension of the telomeres grants an unlimited cellular replication potential in somatic cells 
through the evasion of expressing this senescence-like phenotype. Once a cell enters the state of 
irreversible cellular senescence, its replicative potential becomes zero even though it is otherwise 
a healthy and metabolically active cell. This ground breaking discovery catalyzed the production 
of a novel strategy to combat TNBC through the use of novel molecules that effectively target 
telomere/telomerase complex, and eventually hinder their proliferation rates (2).  
There are two main classes of telomerase inhibitors, each affecting a different site of 
function for the telomerase enzyme. One is known as a nucleoside reverse transcriptase inhibitor 
(NRTI) which is disguised as a nucleoside base used in transcription which will then disrupt the 
replicative chain. The other class is known as non-nucleoside reverse transcriptase inhibitors 
(NNRTI) which will non-competitively bind to the telomerase enzyme. One well-documented 
synthetic agent known as BIBR1532 belongs to the class of NNRTIs and can effectively bind to 
the enzyme, halting the enzymatic activity. The specific inhibitory mechanism of this NNRTI is 
not completely understood, though there are two main theories that have become generally 
accepted. The first states that BIBR1532 attaches to a binding site near enough to the binding site 
for replication that it blocks the replication binding site and thus hindering telomerase; the 
second, BIBR1532 causes a conformational change in the structure of the telomerase enzyme 
after binding to it which will then block the replication binding site from being active (4). 
Essentially both of these compounds directly impede upon the unlimited proliferative capacity of 
cancerous cells, slowing their propagation, and eventually stopping the disease’s progress.  
A novel analogue of the NNRTI, BIBR1532, called GV6 was developed at Grand Valley 
State University and its potential as an anti-tumor/anti-telomerase agent is currently unknown. 
Therefore, our goals were to compare the short-term and the long-term anti-proliferative effects 
of GV6 on MDA-MB 231 TNBC cells to the previously investigated telomerase inhibitor 
BIBR1532, as well as to compare the effectiveness of the two inhibitors on the induction of a 
senescence-like phenotype in the cells. Our hypothesis is that the anti-proliferative and 
senescence inducing effects of GV6 will parallel that of BIBR1532.  
 
Methods 
Cell line 
TNBC cells (MDA-MB231) were seeded into T-75 Ventilated Culture Flasks and cultured in 
RPMI (Life Technologies, NY) media supplemented with 10% fetal bovine serum (Innovative 
Research, MI) plus 100 unit/ml penicillin, 100 µg/ml streptomycin and 0.25 µg/ml Amphotericin 
B (Life Technologies, NY) in an incubator set at 37 °C and 5% CO2. 
Treatment 
Cells were seeded at a density of 1.00 x 106 cells/ml and left undisturbed for 72 hours in RPMI 
control media to allow acclimation to the culture conditions. After the 72 hours had transpired, 
the media was aspirated and replaced with fresh RPMI media supplemented with either Solvent 
(5% DMSO) alone [control] (n=3), 25µm GV6 (n=4), or 25µm BIBR1532 (n=4). 
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Figure 1: The Chemical structure
intellectual property and therefore its structure has not been shown.
Viability Assessment 
At days 5, 9, 14, 18, and 27 of culture in 
evaluated using a hemocytometer and the live to 
Blue Exclusion Test (Life Technologies, NY). 
more permeable which allows the Trypan Blue Stain 
blue. The Number of live/dead cells was estimated by counting and averaging the number of 
cells within the set of four defined grids u
Senescence Test 
A commercially available Senescence
Signaling Technology, MA) was used on days 14 and 27 to detect the cellular activity of 
galactosidase in the lysosomes at slightly acidic pH 6.0. The percentage of SA
cells was estimated by counting the number of blue
an inverted microscope (Olympus, PA; 100X)
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Figure 2: Micrograph of MDA-MB 231 Cells illustrating (i) cells exhibiting 
phenotype (S) and Non-senescence (Replicatively Active) cells (A) [400X magnification], and 
(ii) viable and non-viable cells on 
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Statistics 
Statistical analysis was done using the computer program SPSS (Statistics Version 20, IBM 
Corporation NY). Difference of P < 0.05 w
 
Results 
Figure 3: To determine the effect of 
were seeded at a density of about 
Solvent (n=3) or Solvent-free  (RPMI alone)
After culture for five and nine days
using the Trypan-Blue exclusion test
flasks exhibited a corresponding 
density peaked in both treatments at
that the presence of 5% DMSO in the media
231 cells. Therefore, the difference noted in cell kinetics during our
justifiably attributed to the effects 
DMSO. 
as considered significant. 
the Solvent (DMSO 5%) on the MDA-MB 231 cells, 
1.00 x 106 cells/ml in RPMI media supplemented with 
 (n=3).  
, assessment of the live/dead ratio was 
 and data are presented as Mean ± SD. At day 5, both trial 
cell density of roughly 1.50 x 106 cells/ml. By day 9 the cells 
 approximately 2.00 x 106 cells/ml. These results indicate 
 has no effect on growth kinetics of the MDA
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of the GV6 and BIBR1532, and not to the presence of 5
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Figure 4: The number of viable MDA
BIBR1532 at days 5, 9, 14, 18, and 27 
(n=3). The cell counts are expressed 
as Mean ± SD. The anti-proliferative effects of the compounds are shown 
The ab, ac, ad, ae, and af means within each 
means between the treatments at each
During the short-term treatment trial
(40%) supplemented media was almost double of GV6 (20%)
corresponding growth deficits were noted under both treatments.
depicted a comparable drop in number of viable cells at days 9 (~50%),
(~30%), relative to Solvent-control
indicate that GV6 has an anti-proliferative 
the TNBC cells. These results parallel
inhibitor that indicate the effectiveness of BIBR1532 as a telomerase inhibitor
demonstrate a similar negative effect on the growth kinetics of the 
to nearly 25% of the proliferation rates of the 
next step would be to compare and contrast the
and validate whether it corresponds to published
a 
b 
-MB 231 cells in media supplemented with GV6 and 
had been determined using the Trypan-Blue 
as percents relative to Solvent-Control and d
to be time dependent. 
of the treatment are significantly different (p<0.05) and 
 point a, b, c, d, e, and f are not statistically different
, the decrease in the number of viable cells in 
 by day 5. However, 
 Long-term treatment
 18 (~45%) and 27 
, respectively. Both, the short-term and long-term trials
effect that mirrors the overall effect of BIBR1532
 the current published literature on small molecule 
, as well as 
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control cells at concentration of 25µ
 dose-dependent curves of BIBR1532 and GV6 
 results.  
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Figure 5: Number of dead MDA
at days 5, 9, 14, 18, and 27 in comparison to 
exclusion test (n=3-5). Data are shown as Mean ±
 The amount of dead cells was approximately
(2.00 x 106 cells/ml) and fluctuated only a negligible amount 
that GV6 and BIBR1532 do not c
the proliferation rate of the cells. 
A 
a a 
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c 
-MB 231 cells in media supplemented with GV
Solvent-Control as determined by Trypan
SD.  
 5% of the normal live-cell rate of S
throughout the trials. This 
ause an increase in the rate of cell death but, instead
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Figure 6: Number of (A) senescent cells/treatment in comparison to Control (Solvent), and (B) 
non-senescent (replicatively active) cells on days 14 and 27 of treatment. Data are shown as 
Mean ± SD. ab, ac, ad, and ae, means within each panel are significantly different (p<0.05).  
The time dependent increase in the number of cells expressing a senescence-like phenotype is 
equivalent for GV6 and BIBR1532. By day 14, GV6 and BIBR1532 supplemented flasks have 
approximately double the number of senescent cells in comparison to Solvent-control and the 
number of replicatively active cells corresponds between the two treatments.  A three-fold 
increase in the number of senescent cells and a nearly 70% reduction in the number of active 
cells was observed for both treatments by day 27. 
 
Conclusion and Future Projects 
 This study illustrates that the anti-proliferation effect of GV6 is as potent as BIBR1532 in 
inhibiting rates of triple-negative breast cancer cells both in the short- and long-term setting. The 
ability of GV6 to effectively induce a senescence-like phenotype in treated cells has also been 
observed. Further studies include using real time PCR to determine the level of relative gene 
expression in treatment supplemented cells as opposed to solvent supplemented cells and 
quantifying the levels of telomerase expression in the cells.  
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